Study protocol

Design and baseline characteristics of a prospective cohort study for determinants of osteoporotic fracture in community-dwelling elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study

Masayuki Iki*1, Yuki Fujita1, Junko Tamaki1, Katsuyasu Kouda1, Akiko Yura1, Eiko Kadowaki1, Yuho Sato2, Jong-Seong Moon3, Nozomi Okamoto4, Norio Kurumatani4 and Study Group for Functioning Capacity and Quality of Life in Elderly Japanese (Fujiwara-kyo Study Group)

Address: 1Department of Public Health, Kinki University School of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan, 2Department of Human Life, Jini-ai University, 3-1-1 Ootemachi, Echizen, Fukui 915-8586, Japan, 3Faculty of Human Sciences, Taisei Gakuin University, 1030-1 Hirao, Mihara-ku, Sakai, Osaka 587-8555, Japan and 4Department of Community Health and Epidemiology, Nara Medical University School of Medicine, 840 Shijicho, Kashihara, Nara 634-8521, Japan

Email: Masayuki Iki* - masa@med.kindai.ac.jp; Yuki Fujita - yfujita@med.kindai.ac.jp; Junko Tamaki - jtamaki@med.kindai.ac.jp; Katsuyasu Kouda - kouda@med.kindai.ac.jp; Akiko Yura - ayuko@med.kindai.ac.jp; Eiko Kadowaki - eiko@med.kindai.ac.jp; Yuho Sato - y-sato@jindai.ac.jp; Jong-Seong Moon - mjs@tgu.ac.jp; Nozomi Okamoto - onozomi@nmu-gw.naramed-u.ac.jp; Norio Kurumatani - knorio@nmu-gw.cc.naramed-u.ac.jp; Study Group for Functioning Capacity and Quality of Life in Elderly Japanese (Fujiwara-kyo Study Group) - knorio@nmu-gw.cc.naramed-u.ac.jp

* Corresponding author

Abstract

Background: Osteoporosis and osteoporotic fracture in men are significant public health problems in an aging society. However, information on male osteoporosis remains impressively lacking, especially for Asians. We designed the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study as an ancillary study of a cohort study, the Fujiwara-kyo study, to determine risk factors for osteoporotic fractures in Japanese men.

Methods/Design: Design: A community-based single-centre prospective cohort study with at least a 5-year follow-up

Subjects: All the male participants of the Fujiwara-kyo study who were living in the four cities studied, aged 65 years and older, and able to walk without aid from others.

Primary outcome: Incidence of osteoporotic fractures including vertebral and clinical non-vertebral fractures.

Additional outcomes: Change in bone mineral density (BMD), change in hip geometry, onset of receiving benefits from Long-term Care Insurance (LCI), health-related quality of life, and mortality.

Baseline measurements: BMD at the lumbar spine (LS) and hip (TH), hip geometry, vertebral deformity assessment, bone turnover markers, physical and cognitive performance, various medical
Background

Osteoporotic fracture is a significant and increasing public health burden, for men as well as women, in aging societies. The lifetime risk for osteoporotic fracture was estimated to be 40% in women and 13% in men [1]. These figures, however, may be underestimated by nearly half, and have been suggested to be as high as 23% in men when taking future reduction of mortality into account [2]. The incidence of hip fracture, the most serious osteoporotic fracture, is increasing. The number of hip fractures is projected to be 13 million in 2050, with 31% of these (approximately 4 million), occurring in men [3]. It has been well established that the incidence rate of hip fracture is much higher in Caucasians than in Asians [4], but Asians will account for 45% of hip fractures globally in 2050 because the population of elderly people in Asia is increasing dramatically [3]. In Japan, nation-wide surveys for the incidence of hip fracture have been conducted four times since 1987 [5]. There were 117,900 incident hip fractures estimated in 2002, double the number from 1987, of which 22% occurred in men [6]. This trend in the incidence of osteoporotic fractures urges us to establish a comprehensive strategy to prevent and manage osteoporosis in men as a national and international issue with the highest priority.

In spite of the magnitude of the problem posed by osteoporosis in men, there remains a substantial shortage of information concerning male osteoporosis, especially in Asia. Only a few prospective cohort studies have been performed for the determinants of osteoporotic fracture in Hong Kong Chinese men [7] and in Japanese men [8-10]. Some of these have been well performed with a sufficiently high follow-up rate, but the sample size did not exceed 800, which was not sufficiently large for evaluating determinants of osteoporotic fractures [8-10]. Furthermore, comprehensive geriatric assessments for the evaluation of risk factors for osteoporotic fracture are lacking. Without these data, it would be difficult to design rational clinical and preventive approaches for osteoporosis and osteoporotic fracture in men. Thus, we have designed and launched the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study, a large-scale community-based single-centre prospective cohort study for elderly Japanese men, to address the following questions:

1. Does bone mass predict fracture risk in men as has previously been demonstrated in women?
2. Which lifestyle or medical factors are associated with fracture risk in men?
3. Do physical performance test results predict fracture risk in men?
4. Do bone turnover markers enhance the predictive value of bone density and other clinical risk factors for fracture risk in men?
5. Does socioeconomic status affect the risk of osteoporosis and osteoporotic fracture in men?
6. To what extent do fractures in men increase the risk of being dependent on care provided from Long-term Care Insurance (LCI)?
7. To what extent do fractures affect quality of life (QOL) in men?
8. Do existing vertebral fractures and incident non-vertebral fractures increase risk of death in men?
We present in this paper the design of the FORMEN study and the baseline characteristics of its participants.

**Methods/Design**

**General study description**

The FORMEN study is an ancillary study of a larger prospective cohort study, The Cohort Study for Functioning Capacity and Quality of Life in Elderly Japanese (Primary Investigator: Norio Kurumatani, M.D., Ph.D., Professor and Chairman, Department of Community Health and Epidemiology, Nara Medical University School of Medicine), which is referred to as the “Fujiwara-kyo study” after the study area where the first capital of Japan, called “Fujiwara-kyo,” was established in 694 AD. The Fujiwara-kyo study aims to provide a scientific basis for a comprehensive strategy to prevent frailty, increase the number of healthy life years, and promote the functioning capacity and quality of life of the elderly men and women in Japan. The FORMEN study examines male participants of the Fujiwara-kyo study for bone health. Most of the non-skeletal measurements and interviews were conducted under the Fujiwara-kyo study, and these data form a comprehensive geriatric and gerontologic basis for the FORMEN study to evaluate risk factors of osteoporosis and osteoporotic fracture of elderly men. Brief explanations of the Fujiwara-kyo study appear in this paper and details of the study are described elsewhere. (Kurumatani N, Okamoto N, Morikawa M, Iwamoto J, Hazaki K, Harano A, Tanaka K, Minematsu A, Tomioka K, Saeki K, Amano N, Yanagi M: Protocol and baseline data of a prospective cohort study (Fujiwara-kyo study) on the change of functioning capacity and quality of life among physically independent elderly people: A report from a world’s top longevity country, Japan, submitted)

**Study population and recruitment of samples**

To achieve the aims of the Fujiwara-kyo study, participants in the study should be representative of elderly men and women who are still living independently in a community and can participate in various preventive activities conducted by their municipalities. For the inclusion criteria, therefore, participants should be:

1. aged 65 years or older at baseline,
2. living in their homes in the cities of Kashihara, Nara, Yamato-Kooriyama, and Kashiba, which are surrounding areas of the Nara Medical University Hospital (Figure 1),
3. able to walk without the assistance of another person,
4. able to provide self-reported information, and
5. able to understand and provide written informed consent.

The FORMEN study included all the male participants of the Fujiwara-kyo study.

The recruitment of participants was conducted by the Administrative Centre of the Fujiwara-kyo study with the cooperation of local residents’ associations and elderly people’s clubs organized in every district of the cities studied. These groups used printed literature that included information on the aims of the study, study procedures, risks and benefits posed by study measurements, rights and responsibilities of participants and researchers, publication of results, and protection of privacy. The participants were asked to give written informed consent before enrolment in the study.

The sample sizes necessary for the Fujiwara-kyo study and the FORMEN study were set as 4500 and 2000 as described later, respectively.

**Outcome indices**

The primary outcome for the FORMEN study is the incidence of osteoporotic fractures, including vertebral fractures and clinical non-vertebral fractures. The additional outcomes consist of change in bone mineral density (BMD), change in hip geometry, onset of receiving benefits from LCI, which is an objectively assessed index of having become physically or cognitively dependent on other people in daily life, change in QOL, and death.
**Study measures**

**Skeletal measures**

**Bone mass measurement**

Bone mineral content (BMC) (g) and bone area (cm²) were measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine (L2-4) and right hip in a posteroanterior projection (QDR4500A, Hologic Inc., Bedford, MA, USA) as previously described [11]. Participants with either a history or incident involvement of fractures or bone disease in the right hip were scanned on the left side. We excluded densitometric data of the spine for participants with vertebral fractures or grade four osteophytes according to Nathan’s classification [12], or those with hip deformities in the regions of interest (ROI), from the analysis. All spine and hip measurements throughout the study were made with one scanner installed in a mobile test room in a large vehicle. BMD (g/cm²) was obtained by BMC divided by bone area at the lumbar spine (LS) and total hip (TH). TH was divided into several regions including the femoral neck (FN) and trochanter (TR). The short-term precision as measured by the coefficients of variation (CV) of the BMD measurements in vivo was 1.2%, 1.2%, 1.6% and 1.9% for LS, TH, FN and TR, respectively. Quality assurance of the measurements was conducted daily before the study measurements began. We observed no remarkable drift in BMD values for the spine phantom throughout the baseline study period.

We defined osteoporosis as BMD values 2.5 SD or more below the young adult mean (YAM) [13], and low BMD as 1 SD or more below YAM, in accordance with the WHO criteria [14].

**Hip geometric assessment**

The archived DXA image used for calculating BMD at the hip was subsequently analyzed using Apex software’s Hip Structure Analysis (HSA) program (Hologic Inc., Bedford, MA, USA). The precise method has been described elsewhere [15]. The HSA program automatically set three ROIs defined as: (1) narrow neck, traversing the narrowest width of the femoral neck, (2) intertrochanter, along the bisector of the shaft and femoral neck axes, and (3) shaft, at 1.5 times the minimum neck width distal from the intersection of the neck and shaft axes. The HSA program yielded several hip geometric indices including cross-sectional area, cross-sectional moment of inertia, section modulus, cortical thickness and subperiosteal diameter for each of three ROIs.

**Vertebral deformity assessment**

We imaged the thoracolumbar vertebrae of each participant by single-energy X-ray absorptiometry (SXA) following bone density measurements. Bone morphometric software (QDR4500A Lateral Image Analyze, Hologic Inc., Bedford, MA, USA) was used to measure anterior, central and posterior edge heights of each vertebra using the SXA images. We diagnosed vertebral deformities according to the McCloskey-Kanis criteria [16] and used these as a proxy for vertebral fracture in the baseline study. We visually confirmed all deformed vertebrae according to Genant’s semiquantitative assessment method [17].

**History of symptomatic fractures**

History of symptomatic fracture was determined by interviewer-confirmed self-reports from participants. When a participant reported a symptomatic fracture having occurred at any time of his life, a trained registered nurse conducted an in-person interview to determine when the injury occurred, which bone or part of body was injured, what activities the participant was engaged in when injured, and whether a physician diagnosed the injury as a fracture according to radiographic examinations. We defined a symptomatic fracture as one which caused a clinic visit due to pain and was diagnosed as a fracture by a physician using radiographs.

**Bone turnover markers and other laboratory measures**

We drew blood from each participant after an overnight fast and obtained serum for several conventional biochemical tests planned in the Fujiwara-kyo study. We stored the remaining serum at -80°C until we performed measurements for the FORMEN study. We measured levels of bone turnover markers including osteocalcin (OC), undercarboxylated OC (ucOC), and tartrate-resistant acid phosphatase isoenzyme 5b (TRACP-5b). In addition, we will measure Type I collagen cross-linked C-terminal telopeptide (CTX) and type I procollagen N-terminal propeptide (P1NP). As non-skeletal markers, we measured serum levels of high-sensitivity CRP and homocysteine.

We measured OC [ng/ml] using a two-site immunoradiometric assay (BGP IRMA kit Mitsubishi, Mitsubishi Kagaku Iatron Inc., Tokyo, Japan) with a sensitivity of 1 ng/ml [18]. The precision of this measurement was 4.9%, 3.7% and 6.1% for intraassay CV, interassay CV and overall CV, respectively.

We used an electrochemiluminescence immunoassay to measure ucOC [ng/ml] (Picoluni ucOC, Sanko Junyaku Co. Ltd., Tokyo, Japan) with a sensitivity of 0.39 ng/ml [19]. The precision of this measurement was 4.1%, 3.5% and 5.4% for intraassay CV, interassay CV and overall CV, respectively.

TRACP-5b was measured by a fragment-absorbed immunoassay enzyme assay (Osteolinks-TRAP-5b, Nitto Boseki, Kooriyama, Japan) with a sensitivity of 19.2 mU/dl [20]. The intraassay CV, interassay CV and overall CV of this measurement in our laboratory were 4.9%, 7.3% and 8.8%, respectively.
Serum levels of CTX and P1NP will be measured using an enzyme-linked immunoassay (Serum CrossLaps ELISA, Immunodiagnostic Systems Ltd., Boldon, UK)\[21\] and a two-site electrochemiluminescence immunoassay (Roche Elecsys 2010, Roche Diagnostics, Lewes, UK)[22], respectively.

**Non-skeletal measures**
Non-skeletal measures were obtained in the Fujiwara-kyo study. We state briefly here some measures relevant to the FORMEN study.

**Clinical measures**
We measured participant height (cm), weight (kg) and waist circumference (cm), and calculated body mass index (BMI)(kg/m²).

**Physical and cognitive performance measures**
A series of physical performance tests for elderly people were conducted including grip strength, muscle strength of knee extensors and flexors, brisk gait speed, the timed up-and-go test, and the timed one-leg balance with eyes open. To quantify cognitive function, participants completed the Modified Mini-Mental State Examination [23].

**Medical history, and gerontological lifestyle and socioeconomic factors**
Participants completed a questionnaire including 250 items covering medical history including thyroid diseases, parathyroid diseases, rheumatoid arthritis, connective tissue diseases, malignant diseases, hypertension, diabetes mellitus, coronary heart diseases, hyperlipidemia, asthma, kidney diseases and prostate diseases, history of medications due to these diseases, several scales of geriatric and gerontological factors, smoking and drinking history, diet history including intake of dairy products and a fermented soy bean product called ‘natto’ in Japanese, physical activity indices necessary for quantification using the International Physical Activity Questionnaire (IPAQ) [24], fall and fracture history, family history of fractures, symptoms in back and joints, level of education, social and economic status, and marital status. Participants were asked to bring current prescriptions of medications to the baseline visit where interviewers recorded the name and dose of the medications. Participants were also asked to complete a seven-day diary of their diets to estimate dietary nutrient intakes.

**Quality of life assessment**
Health-related quality of life was assessed with the 36-item short form of the Medical Outcomes Study Questionnaire (SF-36) [25].

**Outcome surveillance**
To obtain outcome indices, annual mail surveys and a follow-up survey in the fifth year comprising similar study items to the baseline study will be conducted as part of the Fujiwara-kyo study.

**Incident vertebral fractures**
An incident vertebral fracture is diagnosed morphometrically based on SXA images of the spine when the anterior, central or posterior height of a vertebra is reduced by 20% or more on follow-up compared to baseline, and when the vertebra also satisfied the McCloskey-Kanis criteria [16]. Vertebralae with heights reduced by 20% or more which do not satisfy the McCloskey-Kanis criteria are considered to be incident fractures if they satisfy the definition of grade 2 or 3 fracture by the Genant method [17].

**Change in bone density and hip geometry**
Bone densitometry will be conducted in the follow-up survey at the same skeletal sites with the same densitometer as used in the baseline study. Changes in BMD at LS, TH, FN and TR, and in hip geometry indices will be determined.

**Non-vertebral and symptomatic vertebral fractures**
When a participant reports on the annual questionnaire the occurrence of fracture in the previous year, a trained nurse will conduct a telephone interview and obtain details of the injury to determine whether the injury is a fracture or not. Reviews of participant medical records will be further conducted with the written permission of the participant.

**Onset of receiving benefits from LCI and death of participants**
We will obtain information regarding whether a participant starts receiving benefits from LCI from response to the annual questionnaire. In the case that a participant dies in the previous year, the family is to inform the Administrative Centre of the Fujiwara-kyo study of the participant’s death. When a participant does not respond to the annual questionnaire, the Administrative Centre will contact the city office and obtain the information on the participant’s receipt of benefits and survival. Participants have given the researchers their consent to this inquiry.

**Statistical analysis**

**Primary analyses**
The primary analyses consist of assessments of baseline risk factors for the primary and additional outcomes of the study. The risk factors will be thoroughly investigated from among the skeletal and non-skeletal measures obtained at baseline. To evaluate risk factors for vertebral fractures and clinical non-vertebral fractures, we will conduct logistic regression analysis and Cox proportional hazards regression analysis, respectively. Factors associated with changes in BMD and hip geometry indices will be evaluated by multiple regression analysis. The proportional hazards regression will also be applied to evaluate...
risk factors for receiving benefits from LCI, and mortality. Determinants for changes in QOL will be evaluated by multiple regression analysis. Additional effects of the incidence of osteoporotic fractures during follow-up on receiving LCI benefits, changes in QOL and survival will be evaluated after adjusting for their potential risk factors at baseline.

Additional analyses
Additional analyses, mostly cross-sectional, are being conducted for provisional assessments of known and potential risk factors for the outcome indices. These include the effects of socioeconomic status, medical histories, physical and cognitive performance, and lifestyle factors including smoking, drinking, milk consumption and "natto" intake on BMD, low BMD, and vertebral fractures.

Sample size calculations
The sample size necessary for the FORMEN study was set as 2000. This was obtained in order that the logistic regression analysis yields a significant estimate with a two-tailed level of significance at 5% and a statistical power of 80% for a risk factor of fracture which exists in 20% of the population and increases the fracture risk by 75% compared with people without the risk factor who run the absolute fracture risk of 1% per year. The statistical power afforded by the sample size of 2000 under several other assumptions is shown in Table 1.

Sample size calculations
The sample size necessary for the FORMEN study was set as 2000. This was obtained in order that the logistic regression analysis yields a significant estimate with a two-tailed level of significance at 5% and a statistical power of 80% for a risk factor of fracture which exists in 20% of the population and increases the fracture risk by 75% compared with people without the risk factor who run the absolute fracture risk of 1% per year. The statistical power afforded by the sample size of 2000 under several other assumptions is shown in Table 1.

| Risk factor studied | Annual incidence rate of fracture (%) in population without a risk factor studied |
|---------------------|----------------------------------------------------------------------------------|
| Prevalence rate (%) | RR 0.8 | 1 | 1.5 | 2 | PARP (%) |
| 20                  | 1.25  | 14 | 18  | 24 | 41 | 4.8 |
|                     | 1.5   | 41 | 50  | 68 | 81 | 9.1 |
|                     | 1.75  | 72 | 81  | 94 | 99 | 13.0 |
| 30                  | 1.25  | 17 | 21  | 30 | 38 | 7.0 |
|                     | 1.5   | 43 | 59  | 78 | 89 | 13.0 |
|                     | 1.75  | 80 | 88  | 98 | 100| 18.4 |
|                     | 2     | 95 | 98  | 100 | 100 | 23.1 |
| 40                  | 1.25  | 19 | 23  | 32 | 42 | 9.1 |
|                     | 1.5   | 53 | 63  | 81 | 92 | 16.7 |
|                     | 1.75  | 83 | 91  | 98 | 100| 23.1 |
|                     | 2     | 96 | 99  | 100 | 100 | 28.6 |

Statistical power was estimated for a logistic regression analysis to yield a significant estimate for a risk factor with a two-tailed level of significance at 5% under a sample size of 2000 with various combinations of assumptions.

RR: Relative risk of fracture posed by a risk factor studied.
PARP: Population attributable risk proportion.
**Boldface**: Power > 80%
81: Assumptions used when the present sample size of 2000 was determined.
The FORMEN Administrative Center is organized in the Department of Public Health, Kinki University School of Medicine, to conduct the FORMEN study smoothly in close cooperation with the Fujiwara-kyo study.

The study protocol of the Fujiwara-kyo study was approved by the Medical Ethics Committee of the Nara Medical University, and that of the FORMEN study was approved by the Ethics Committee of the Kinki University School of Medicine.

**Current status**

**Participant recruitment**

During the baseline study period, 2174 men and 2253 women participated in the Fujiwara-kyo study. Among the male participants, 2012 men completed the measurements conducted in the FORMEN study and were eligible for further analyses and the cohort study. The average age of the participants was 73.3 ± 5.3 (mean ± SD) years with a range of 65 to 94 years. They were 162.8 ± 5.7 cm tall, weighed 60.9 ± 8.6 kg, and had a mean BMI of 22.9 ± 2.8.

Table 2 shows comparisons of age distribution and body size parameters between FORMEN study participants and the male population of Nara Prefecture[26,27] or Japan [26,28]. The FORMEN participants comprised a higher proportion of men aged 70-79 and were slightly taller than the general population of Japan, but were very similar in body size to men in Nara Prefecture.

**Characteristics of participants**

**Medical history and lifestyle factors**

Medical history and lifestyle factors of the study participants are listed in Table 3. The prevalence rate of cerebrovascular diseases and malignant diseases including prostate cancer increased with aging. Lifestyle factors listed in this table were all significantly related to age. With the increase in age, participants drank more milk, smoked less, drank less alcohol and expended less energy. We also obtained information regarding other lifestyle factors, including dietary intake and exercise history, which will be presented in future publications.

**Skeletal measures**

Skeletal measures of the study participants are shown in Table 4, stratified by age. BMD and BMC at LS were not significantly correlated with age, while those at TH, FN and TR were. Bone area did not clearly show an association with age. When adjusted for height and weight, BMD at TH still decreased with age (partial regression coefficient of -0.016 [SE 0.005] g/cm² /10 years [p < 0.0001]), but BMD at LS increased significantly (0.042 [0.008] g/cm² /10 years [p < 0.0001]). The levels of biochemical markers, such as OC, ucOC, and TRACP-5b increased with aging as well.

**Table 2: Age and body size between FORMEN participants and male population of Nara Prefecture or Japan**

| Index         | Population                  | 65-69 years | 70-74 years | 75-79 years | 80 years and older |
|---------------|-----------------------------|-------------|-------------|-------------|-------------------|
| Age distribution | FORMEN study               | 627 (31.2%) | 705 (35.0%) | 450 (22.4%) | 230 (11.4%)       |
|               | Nara Prefecture[26]        | 34.7%       | 28.0%       | 20.3%       | 16.9%             |
|               | Japan[26]                   | 33.2%       | 28.1%       | 20.6%       | 18.1%             |
| Height (cm)   | FORMEN study                | 164.8 ± 5.9 | 163.2 ± 5.9 | 162.7 ± 6  | 160.5 ± 6.4       |
|               | Nara Prefecture[26]        | 165.5 ± 6.2 | 164.1 ± 6.3 | 162.3 ± 6.3| 160.5 ± 6.8       |
|               | Japan[26]                   | 163.7 ± 6.5 | 162.2 ± 6.9 | 161.0 ± 6.3| 158.9 ± 8.0       |
| Weight (kg)   | FORMEN study                | 63.3 ± 9.1  | 62.0 ± 8.6  | 60.0 ± 8.6  | 56.8 ± 8.8        |
|               | Nara Prefecture[26]        | 64.1 ± 9.2  | 62.8 ± 9.5  | 60.1 ± 9.2  | 56.6 ± 9.9        |
|               | Japan[26]                   | 64.4 ± 9.7  | 62.0 ± 8.7  | 59.7 ± 8.4  | 56.0 ± 9.6        |
| BMI (kg/m²)   | FORMEN study                | 23.7 ± 3.2  | 23.7 ± 3.1  | 23.1 ± 3.3  | 22.4 ± 3.3        |
|               | Nara Prefecture[26]        | 23.8 ± 3.3  | 23.8 ± 3.4  | 23.2 ± 3.5  | 22.4 ± 3.6        |
|               | Japan[26]                   | 24.4 ± 3.6  | 24.0 ± 3.4  | 23.4 ± 3.1  | 22.6 ± 3.5        |

[26] Population Statistics based on the Basic Resident Registry [26]
[27] Annual Report of Basic Health Examinations 2007 [27]
[28] National Health and Nutrition Survey 2006 [28]
The prevalence rates of osteoporosis in the FORMEN participants were 3.5% at LS, 1.9% at TH, and 4.4% in at least one of LS and TH. The prevalence rates of low BMD were 26.4%, 33.9% and 41.8%, respectively. Figure 3 illustrates proportions of low BMD categories in the participants in 10-year age groupings. The proportion of men whose BMD was judged to be low only at TH showed a significant increase with increase in age (p < 0.0001), while low BMD only at LS showed a decreasing trend with increasing age (p = 0.0386). Diagnosis of low BMD was not well correlated with BMD at LS and TH, with a kappa coefficient of 0.45. Other skeletal measures, including diagnosis of vertebral deformities and hip geometry indices, are being analyzed and will be presented in future papers.

Non-skeletal measures
Physical performance tests and cognitive performance tests were carried out successfully in most participants. The database is under construction and the results will be presented in future reports. We were also successful in obtaining QOL indices.

Discussion
The FORMEN study is a large-scale community-based single-centre study for elderly Japanese men with comprehensive geriatric and gerontologic assessments for potential risk factors of osteoporosis and osteoporotic fractures. We have successfully conducted the baseline study as designed, and will carry out longitudinal observations for at least five years as a prospective cohort study.

The FORMEN study has some strengths compared with previous studies. First, the sample size of the FORMEN study is the largest in Japan, allowing for a high enough statistical power to evaluate risk factors of vertebral or osteoporotic fractures. Second, it has a comprehensive coverage of skeletal measures relevant to osteoporosis assessment, including vertebral deformity assessment and HSA in addition to conventional BMD measurement. Third, biochemical markers of bone turnover in sera were measured for all participants, and the remaining sera are stored at -80°C for further measurements of newer markers. Fourth, it has comprehensive coverage of potential

Table 3: Baseline characteristics of participants stratified by age in the FORMEN baseline study, 2007-2008

| Past history and present involvement of diseases (%) | All age groups | 65-69 years | 70-74 years | 75-79 years | 80 years and older | P value * |
|-----------------------------------------------------|---------------|-------------|-------------|-------------|-------------------|-----------|
| Thyroid diseases                                    | 1.4           | 1.3         | 1.3         | 0.7         | 3.9               | 0.0915    |
| Rheumatoid arthritis and connective tissue diseases| 1.0           | 1.0         | 0.9         | 0.7         | 2.2               | 0.3419    |
| Diabetes mellitus                                   | 10.1          | 9.4         | 10.7        | 10.9        | 8.7               | 0.9221    |
| Asthma                                              | 1.2           | 1.6         | 0.7         | 1.3         | 1.3               | 0.7719    |
| Hypertension                                        | 33.3          | 30.2        | 35.0        | 35.6        | 31.7              | 0.2787    |
| Cerebrovascular diseases                            | 3.7           | 2.6         | 2.8         | 6.4         | 3.9               | 0.0137    |
| Coronary heart disease                              | 4.7           | 4.3         | 4.6         | 4.9         | 5.7               | 0.4090    |
| Malignant diseases                                  | 8.2           | 6.2         | 0.4         | 9.1         | 11.3              | 0.0115    |
| Prostate cancer                                     | 2.4           | 1.6         | 2.1         | 3.8         | 3.0               | 0.0391    |
| Steroid use                                         | 0.9           | 1.1         | 0.6         | 1.1         | 1.3               | 0.7588    |
| Statin use                                          | 4.9           | 4.8         | 5.4         | 3.1         | 7.0               | 0.8217    |
| Fragility fractures since age 50                    | 4.4           | 1.2         | 4.4         | 4.9         | 4.4               | 0.7019    |

Lifestyle factors

| Milk consumption (%)                               |               |             |             |             |                   |           |
|----------------------------------------------------|---------------|-------------|-------------|-------------|-------------------|-----------|
| 2 glasses/day or more                               | 8.1           | 6.2         | 8.4         | 9.1         | 10.0              | 0.0088    |
| 1 glass/day                                        | 43.2          | 40.4        | 43.9        | 40.4        | 53.9              |           |
| Several glasses/week                               | 15.2          | 16.6        | 15.5        | 16.2        | 8.7               |           |
| 1 glass/week or less                               | 33.5          | 36.7        | 32.3        | 34.2        | 27.4              |           |

| Smoking status (%)                                 |               |             |             |             |                   |           |
|----------------------------------------------------|---------------|-------------|-------------|-------------|-------------------|-----------|
| Current smokers                                    | 17.0          | 21.9        | 17.3        | 14.3        | 7.9               | <0.0001   |
| Ex-smokers                                         | 61.4          | 56.6        | 59.8        | 65.1        | 71.9              |           |
| Non-smokers                                        | 21.7          | 21.5        | 23.0        | 20.8        | 20.2              |           |

| Number of pack-years in ever-smokers               | 41.1 ± 28.3   | 40.8 ± 28.5 | 43.2 ± 27.8 | 39.2 ± 27.8 | 39.9 ± 29.5       | 0.3908    |

| Alcohol drinking habit (%)                         |               |             |             |             |                   |           |
|----------------------------------------------------|---------------|-------------|-------------|-------------|-------------------|-----------|
| Less than once/week                                | 38.0          | 33.3        | 37.8        | 40.9        | 45.8              | 0.0218    |
| 1-2 times/week                                     | 5.3           | 5.3         | 4.7         | 5.8         | 6.2               |           |
| 3-5 times/week                                     | 8.9           | 10.4        | 8.9         | 7.4         | 7.5               |           |
| 6 times/week or more                               | 47.9          | 51.0        | 48.6        | 45.9        | 40.5              |           |

Values represent mean ± SD, median with interquartile limits in parentheses, or proportion.

* A trend of each variable with aging was tested by a linear regression-based trend test or Cochran-Armitage trend test. Chi-squared test was applied when a variable had more than two categories.
risk factors of osteoporosis and osteoporotic fractures based on geriatric and gerontologic assessments. Fifth, we have established highly reliable surveillance of outcome indices using official municipality databases, including onset of becoming dependent on others in daily life and mortality. Finally, a single-centre study design has an advantage over a multi-centre design with respect to quality control of study performance given that no inter-centre calibrations of study measurements are necessary.

The FORMEN study also has potential limitations. First, participants were not randomly selected, which makes generalizing the results obtained difficult. However, the Fujikawa-kyo study aims to apply the results to people living independently in the communities studied, and our results can be utilized for this purpose. Second, the sample size of the FORMEN study may still be small for assessing risk factors of hip fracture. Third, BMD measurements did not include whole body BMD or volumetric BMD obtained by quantitative computed tomography. Fourth, vertebral deformity detected with SXA images might

Table 4: Skeletal measures of participants stratified by age in the FORMEN baseline study, 2007-2008

| Index | All age groups | 65-69 years | 70-74 years | 75-79 years | 80 years and older | P for trend |
|-------|----------------|-------------|-------------|-------------|-------------------|-------------|
| BMD (g/cm²) |                 |             |             |             |                   |             |
| LS    | 1.026 ± 0.191   | 1.022 ± 0.177| 1.023 ± 0.185| 1.030 ± 0.199| 1.042 ± 0.226     | 0.1877      |
| TH    | 0.878 ± 0.126   | 0.901 ± 0.124| 0.880 ± 0.121| 0.864 ± 0.129| 0.841 ± 0.130     | <0.0001     |
| FN    | 0.740 ± 0.116   | 0.763 ± 0.117| 0.741 ± 0.111| 0.720 ± 0.114| 0.715 ± 0.118     | <0.0001     |
| TR    | 0.604 ± 0.112   | 0.702 ± 0.109| 0.685 ± 0.107| 0.674 ± 0.117| 0.651 ± 0.119     | <0.0001     |
| BMC (g) |                 |             |             |             |                   |             |
| LS    | 54.3 ± 13.3     | 54.2 ± 12.1 | 54.2 ± 13.4 | 54.5 ± 14.1 | 54.4 ± 14.4       | 0.7020      |
| TH    | 36.5 ± 6.1      | 37.4 ± 6.3  | 36.5 ± 5.8  | 36.0 ± 5.9  | 35.2 ± 5.3        | <0.0001     |
| FN    | 3.9 ± 0.6       | 4.0 ± 0.6   | 3.9 ± 0.6   | 3.8 ± 0.6   | 3.8 ± 0.7         | <0.0001     |
| TR    | 8.9 ± 2.5       | 9.2 ± 3.5   | 8.9 ± 1.8   | 8.8 ± 1.8   | 8.3 ± 2.0         | <0.0001     |
| Area (cm²) |                 |             |             |             |                   |             |
| LS    | 51.9 ± 5        | 52.2 ± 4.6  | 51.8 ± 5.1  | 52.0 ± 5.1  | 50.9 ± 5.2        | 0.0039      |
| TH    | 41.6 ± 3.5      | 41.5 ± 3.6  | 41.5 ± 3.4  | 41.7 ± 3.3  | 41.8 ± 3.6        | 0.1959      |
| FN    | 5.3 ± 0.4       | 5.2 ± 0.3   | 5.3 ± 0.4   | 5.3 ± 0.3   | 5.3 ± 0.3         | 0.0801      |
| TR    | 13.0 ± 2.0      | 13.1 ± 2.7  | 13.0 ± 1.5  | 13.0 ± 1.5  | 13.1 ± 1.6        | 0.6968      |
| Biochemical marker of bone turnover |                  |             |             |             |                   |             |
| OC (ng/ml) | 4.8 (3.2, 6.5) | 4.5 (2.6, 6.1)| 4.8 (3.2, 6.5)| 5.0 (3.5, 6.8)| 5.4 (4.0, 6.9)| <0.0001    |
| ucOC (ng/ml) | 2.9 (1.5, 5.4) | 2.7 (1.5, 4.9)| 2.9 (1.6, 5.4)| 3.0 (1.6, 5.7)| 3.4 (1.8, 6.4)| <0.0001    |
| TRACP-5b (mU/dl) | 212.3 (121.7, 370.4)| 200.2 (115.0, 348.7)| 211.0 (120.2, 370.5)| 212.3 (122.0, 369.3)| 254.0 (152.5, 423.3)| <0.0001    |

BMD: Bone mineral density
BMC: Bone mineral content
LS: Lumbar spine TH: Total hip FN: Femoral neck TR: Trochanter
OC: Osteocalcin
ucOC: Undercarboxylated osteocalcin
TRACP-5b: Tartrate resistant acid phosphatase isoenzyme 5b
Values of bone densitometric measures represent mean ± SD.
OC values represent median with interquartile limits in parentheses.
ucOC and TRACP-5b values represent geometric mean with values for M-SD and M+SD in parentheses.
Bone densitometric data at the spine and at the hip were obtained from 1912 subjects with BMD values available for both skeletal sites were used in the analysis.

Number of participants with available measurements for OC, ucOC and TRACP-5b were 1971, 1970 and 2003, respectively.

Figure 3
Proportions of BMD categories in age-stratified participants of the FORMEN baseline study, 2007-2008.

BMD: Bone mineral density. Normal: BMD greater than 1 SD below the young adult mean (YAM). Low BMD: BMD 1 SD or more below YAM. LS: Lumbar spine. TH: Total hip. Data of 1912 subjects with BMD values available for both skeletal sites were used in the analysis.
underestimate the prevalence of vertebral fractures compared to diagnosis with conventional radiographs. Fifth, urinary levels of bone turnover markers were not measured, although more novel serum markers were included. Finally, the deaths of participants will be confirmed, but a survey for the cause of death is not included in the initial study protocol.

Such potential limitations of the FORMEN study may have some effects on the study results, but are not expected to invalidate the results. In turn, they may suggest some directions for future research. The study items of the FORMEN study cover most items of preceding studies, such as the Mr OS study [29]. It may be possible to combine the results with those from other studies to increase the statistical power. Extending the follow-up period of the FORMEN study is worthwhile, and can increase the power as well. New random sample studies may be desirable to generalize study results to the whole population.

Conclusions

The FORMEN study, a large-scale community-based single-centre prospective cohort study for elderly Japanese men with comprehensive coverage of potential risk factors of osteoporosis and osteoporotic fractures, designed as an ancillary study of the Fujiwara-kyo study, was successfully launched for longitudinal observations for at least five years. The study is expected to clarify a range of risk factors for osteoporotic fractures, to form predictive models of fracture risk, and to assess consequences of fractures in Japanese elderly men. These results should help health care professionals improve their preventive activities and management of osteoporosis in men.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

The Fujiwara-kyo Study Group performed most non-skeletal measures in the present study and provided the data to the FORMEN study. MI is the director of the FORMEN study, conceived of and designed the study, conducted the surveys and drafted the manuscript. YF is responsible for the FORMEN Administrative Center and conducted surveys in the study. JT participated in designing the study and conducting the surveys. YS analyzed DXA scan data to yield BMD values. KK was responsible for measurements of bone turnover markers. AY, EK and ISM were responsible for quality control of interview surveys. NO works as a secretary-general of the Administrative Center for the Fujiwara-kyo study. NK, the Principal Investigator of the Fujiwara-kyo study and the Chairperson of the Core Member Committee, conceived of and designed the Fujiwara-kyo study, and participated in designing the FORMEN study. All authors critically revised the manuscript and approved the final version of the manuscript for publication.

Acknowledgements

The Fujiwara-kyo Study Group chaired by Norio Kurumatani with Nozomi Okamoto as a secretary general comprised Nobuko Amano, Yuki Fujita, Akihiro Harano, Kan Hazaki, Masayuki Iki, Junko Iwamoto, Akira Mine-matsu, Masayuki Morikawa, Keigo Saeki, Noriyuki Tanaka, Kimiko Tomioka and Motokazu Yanagi. The FORMEN study was supported by several grants as follows: MI is supported by Grants-in-Aid for Scientific Research (20659103: 2008-2009, B 21390210: 2009-2011) from the Japanese Society for the Promotion of Science, and by a Grant-in-Aid for Study on Milk Nutrition (2008) from the Japan Dairy Association. JT is supported by Grants-in-Aid for Scientific Research (C #20590661: 2008-2010) from the Japanese Society for the Promotion of Science, by a Grant (2007) from the Foundation for Total Health Promotion, and by a St. Luke's Life Science Institute Grant-in-Aid for Epidemiological Research (2008). YF is supported by a Grant-in-Aid for Young Scientists (B #20790451: 2008-2010) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and by a Grant (2008) from the Physical Fitness Research Institute, MEIJIL YASUDA Life Foundation of Health and Welfare. The funding bodies have never had any role in designing the study, in analyzing and interpreting the data, in writing the manuscript, or in deciding where to submit the manuscript for publication. The authors acknowledge Eissi Co. Ltd. (Tokyo, Japan) and Sanko Junyaku Co. Ltd. (Tokyo, Japan) for their cooperation in measuring ucOC in sera, Toyukai Medical Corporation (Tokyo, Japan) and Toyo Medic Inc., (Osaka, Japan) for DXA scanning, and SRL Inc., (Tokyo, Japan) for their technical assistance in laboratory measurements.

References

1. Delmas PD, Frase M: Strong bones in later life: Luxury of necessity? Bull World Health Org 1999, 77:416-22.
2. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA: Lifetime risk of hip fracture is underestimated. Osteoporos Int 1999, 8:599-603.
3. Gullberg B, Johnell O, Kanis JA: World-wide projections for hip fracture. Osteoporos Int 1999, 7:407-13.
4. Ross PD, Norimatsu H, Davis JW, Yano K, Wasnich RD, Fujiwara S, Hosoda Y, Melton LJ: A comparison of hip fracture incidence among native Japanese, Japanese Americans and American Caucasians. Am J Epidemiol 3rd edition. 1991, 133:801-809.
5. Yoshimura N, Suzuki T, Hossu T, Orimo H: Epidemiology of hip fracture in Japan: incidence and risk factors. J Bone Miner Metab 2005, 23(Suppl):78-80.
6. Orimo H, Sakata K: The 4th nationwide survey for hip fracture in Japan. Japan Medical Journal 2006, 4180:25-30. in Japanese
7. Lau EM, Leung PC, Kwok T, W. o. j. Lynn H, Orwell E, Cummings S, Cauley J: The determinants of bone mineral density in Chinese men--results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men. Osteoporos Int 2006, 17:297-303.
8. Yoshimura N, Kinoshita H, Takijiri T, Oka H, Muraki S, Mabuchi A, Kawaguchi H, Nakamura K, Nakamura T: Association between height loss and bone loss, cumulative incidence of vertebral fractures and future quality of life: the Miyama study. Osteoporos Int 2008, 19:21-8.
9. Yoshimura N, Kasamatsu T, Sakata K, Hashimoto T, Cooper C. The relationship between endogenous estrogen, sex hormone-binding globulin, and bone loss in female residents of a rural Japanese community: the Taiji Study. J Bone Miner Metab 2002, 20:303-10.
10. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M: Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 2003, 18:1547-53.
11. Iki M, Kagamimori S, Kagawa Y, Matsuzaki T, Yoneshima H, Harumoto F: Bone mineral density of the spine, hip and distal forearm in representative samples of the Japanese female population: Japanese Population-Based Osteoporosis (JPOS) Study. Osteoporos Int 2001, 12:529-37.
12. Nathan H: Osteophytes of the vertebral column. J Bone Joint Surg 1962, 44-A:243-269.

13. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hoso T, Gorai I, Tanaka H, Igai T, Kishimoto H: Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001, 19:331-7.

14. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khalsaev N: The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:137-41.

15. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU: Predicting femoral neck strength from bone mineral data: a structural approach. Invest Radiol 1990, 25:6-18.

16. McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Yasikaran S, Kanis JA: The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993, 3:138-47.

17. Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK: Recognizing and reporting osteoporotic vertebral fractures. Eur Spine J 2003;12:

18. Kawaguchi H, Matsumoto T, Kurokawa T, Orimo H, Mizunashi K, Takuwa Y, Niimi H, Shiraki M, Ohara T, Shishiba Y, Tsuchiya Y, Takahashi H, Takasaki K, Seino Y, Morii H, Fujita T, Okamoto S, Ogata E: Serum levels of BGP determined by two-site immunoradiometric assay (IRMA) using monoclonal antibodies. Clin Endocrinol 1990, 38:1291-1296. (in Japanese)

19. Nishimura J, Arai N, Tohmatsu J: Measurement of serum under-carboxylated osteocalcin by electrochemiluminescence immunoassay with the "Picolumi uOC" kit. Igaku to Yakugaku 2007, 57:523-535. (in Japanese)

20. Ishihara Y, Inaba M, Ishii K, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, KUrasawa K, Mochiduki Y: Evaluation of newly developed kit for measurement of bone-specific tartrate-resistant acid phosphatase in blood. Igaku to Yakugaku 2005, 54:709-717. (in Japanese)

21. Bonde M, Qvist P, Fledelius C, Riis Bj, Christiansen C: Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps)-follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1999, 80:864-8.

22. The Elecsys 2010 Rack system Roche Diagnostics [http://rochediagnostics.ca/lab/solutions/e2010.php].

23. Teng L, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987, 48:314-318.

24. Craig CL, Marshall AL, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35:1381-1395.

25. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K: Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol 1998, 51:1037-1044.

26. Statistics Bureau and the Director-General for Policy Planning: Population Statistics based on the Basic Resident Registry. Ministry of Health home page [http://www.soumu.go.jp/menu_news/s-news/2008080731_6.html].

27. Division of Vascular Diseases, Advisory Committee for Lifestyle-related Disease Control and Prevention. In Annual Report of Basic Health Examinations 2007 Nara Prefectural Government, Nara; 2008.

28. The Office for Life-style Related Disease Control, the Japanese Ministry of Health, Labor, and Welfare. Report of the National Health and Nutrition Survey 2006, Tokyo 2009.

29. Blank JB, Cawthon PM, Carion-Petersson ML, Harper L, Johnson P, Mitson E, Delay RR: Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemporary Clinical Trials 2005, 26:557-568.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/10/165/prepub

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright